CPT® Code 81596

Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver

The CPT® Code 81596 pertains to a laboratory test specifically designed for the assessment of chronic hepatitis C virus (HCV) infection. This test evaluates the presence of fibrosis and necroinflammatory activity in the liver, providing critical insights into the liver's health without the need for invasive procedures such as liver biopsy. The test measures six key biochemical markers: alanine aminotransaminase (ALT), A2-macroglobulin, apolipoprotein A-1, total bilirubin, gamma-glutamyltransferase (GGT), and haptoglobin. Each of these biomarkers plays a significant role in indicating liver function and damage. The results are interpreted through a prognostic algorithm that incorporates the patient's age, gender, and serum levels of the biomarkers, yielding scores that categorize the extent of fibrosis and inflammatory activity. Specifically, the fibrotic score ranges from 0.00 to 1.00, correlating to a stage score from F0 (no fibrosis) to F4 (severe fibrosis or cirrhosis). Similarly, the inflammatory activity score also ranges from 0.00 to 1.00, with stage scores from A0 (no activity) to A3 (severe activity). This comprehensive approach allows healthcare providers to monitor the progression of liver disease in patients with chronic HCV infection effectively.